In this webinar Josh Apgar, PhD discusses Early Feasibility Assessment (EFA), a quantitative approach to early discovery, to help predict whether a therapeutic has a reasonable chance of success. In this presentation, we’ll…
请参阅我们的《ESG 报告》，了解我们的 ESG 策略如何带来具有影响力的持久变革。
RADNOR, Pa. — 2024 年 10 月 28 日 — Certara, Inc. （纳斯达克股票代码：CERT), a global leader in model-informed drug development, today announced that Company management will participate in the Stephens Annual Investment…
专业非临床药物开发咨询服务，覆盖从先导化合物筛选与确定、推进至首次人体试验（FIH）研究，并提供监管策略支持。
我们的非临床与临床 DMPK 及 ADME 咨询服务为早期药物研发提供全方位支持。
Certara 专家级 CMC 顾问提供 CMC 支持，覆盖药物开发全阶段 — 从早期临床前开发到上市后活动。
Your biotech company has just submitted the marketing application for your first drug product. It’s a moment of celebration after years of hard work! But you know that the reviewers’…
Clients are invited to join Certara at this two-day event to further explore and connect on the future of drug development RADNOR, PA – OCTOBER 24, 2024 – Certara, Inc….
Read this guide to find out the 5 common CDISC SDTM implementation challenges and the best practice solutions to each.
This free guide explores how to automate CRF annotations, the benefits of automation, and the industry requirements you need to know.
© 2025 Certara. 保留所有权力。 | 隐私政策
